COGT241220P9000
- 0.75
- 0.000.00%
Cogent Biosciences Newsroom
Cogent Biosciences Price Target Maintained With a $15.00/Share by Needham
Express News | Cogent Biosciences Inc : Needham Cuts to Hold From Buy
Needham Downgrades Cogent Biosciences(COGT.US) to Hold Rating, Maintains Target Price $15
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
Leerink Partners Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $16
Promising Market Potential for Cogent Biosciences: A Buy Rating Backed by Efficacy and Safety of Bezuclasinib
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Cogent Biosciences Shares Are Trading Lower. The Company Presented Data on Bezuclastinib for Mastocytosis at ASH 2024.
Express News | Cogent Biosciences Inc: Top-Line Results Now Expected in July 2025
Express News | Cogent Biosciences: 56% Mean Improvement in Total Symptom Score at 24 Weeks With 76% of Patients Achieving at Least a 50% Reduction in Tss
Express News | Cogent Biosciences: Updated Clinical Results From Open Label Extension Portion of Summit Trial
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
Strong Efficacy and Safety Profile of Cogent Biosciences' Bezu in Adv SM Outshines Competitors
Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients With Advanced Systemic Mastocytosis (AdvSM)
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $23
Express News | Cogent Biosciences Inc : Guggenheim Cuts Target Price to $17 From $20
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $21
Cogent Biosciences Is Maintained at Buy by Needham
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $15
Cogent Biosciences Analyst Ratings